课题基金 / 基金详情

Radiation Therapy: Dissecting the Role of Stromal Cells in Tumor Control

Radiation Therapy: Dissecting the Role of Stromal Cells in Tumor Control
放射治疗:剖析基质细胞在肿瘤控制中的作用
批准号:
8843808
负责人:
David Guy Kirsch
金额:
$43.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-01 至 2016-01-03

项目摘要

项目成果

David Guy Kirsch的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Radiation therapy is utilized to treat approximately 50% of all patients with cancer. However, a fundamental gap in improving the efficacy of radiation therapy exists because the mechanisms by which radiotherapy controls tumors remain poorly understood. For example, although hypoxia is a well-established cause of resistance to radiation therapy, the signal transduction pathways by which hypoxia regulates tumor response to radiation therapy remains to be fully elucidated. The overall goal of this research is to better understand how the efficacy of radiation therapy is influenced by the tumor stroma and microenvironment. We hypothesize that radiation therapy cures cancer by killing tumor parenchymal cells, but the tumor stroma influences the response of tumor parenchymal cells to radiation by regulating the tumor microenvironment. To study the complex interactions of tumor stroma and parenchymal cells during radiation therapy, we have generated novel genetically engineered mice. Previously, we used Cre recombinase to develop genetically engineered mouse models of soft tissue sarcoma to study radiation biology. We have now generated novel strains of genetically engineered mice in which primary cancers can be generated with Flp recombinase. In this system, Cre recombinase can still be utilized to modify genes specifically in the tumor stroma. Utilizing Flp and Cre recombinases (i.e. dual recombinase technology) to study the tumor microenvironment's impact on radiation therapy is highly innovative because primary cancers can be initiated with one recombinase, while the other recombinase can be utilized to specifically modify tumor stromal cells. The proposed research is significant, because we will dissect the mechanisms by which myeloid cells are recruited to tumors during radiation therapy to regulate tumor response. Ultimately, such knowledge has the potential to lay the foundation for novel approaches to improve the efficacy of radiation therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing Cancer Therapy through Groundbreaking Research in Radiation Biology
  • 批准号:
    10517545
  • 项目类别:
  • 资助金额:
    $95.06万
  • 财政年份:
    2016
  • 负责人:
    David Guy Kirsch
  • 依托单位:
Advancing Cancer Therapy through Ground Breaking Research in Radiation Biology
  • 批准号:
    10064609
  • 项目类别:
  • 资助金额:
    $94.28万
  • 财政年份:
    2016
  • 负责人:
    David Guy Kirsch
  • 依托单位:
Advancing Cancer Therapy through Ground Breaking Research in Radiation Biology
  • 批准号:
    10323262
  • 项目类别:
  • 资助金额:
    $92.39万
  • 财政年份:
    2016
  • 负责人:
    David Guy Kirsch
  • 依托单位:
Advancing Cancer Therapy through Ground Breaking Research in Radiation Biology
  • 批准号:
    9581606
  • 项目类别:
  • 资助金额:
    $5.49万
  • 财政年份:
    2016
  • 负责人:
    David Guy Kirsch
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: